MEI Pharma Future Growth

How is MEI Pharma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

8.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqCM:MEIP - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2025	16	-107	-130	-130	4
6/30/2024	7	-119	-121	-121	5
6/30/2023	24	-91	-107	-107	5
9/30/2022	42	-54	-56	-56	N/A
6/30/2022	41	-54	-49	-49	N/A
3/31/2022	37	-47	-36	-36	N/A
12/31/2021	35	-64	-35	-35	N/A
9/30/2021	36	-60	-35	-35	N/A
6/30/2021	35	-41	-33	-32	N/A
3/31/2021	52	-53	48	48	N/A
12/31/2020	45	-31	52	54	N/A
9/30/2020	33	-43	42	43	N/A
6/30/2020	28	-47	33	34	N/A
3/31/2020	5	-24	-44	-43	N/A
12/31/2019	5	-38	-44	-44	N/A
9/30/2019	6	-5	-31	-31	N/A
6/30/2019	5	-17	-30	-29	N/A
3/31/2019	4	-39	-25	-25	N/A
12/31/2018	4	-28	-20	-20	N/A
9/30/2018	2	-46	-27	-27	N/A
6/30/2018	2	-40	-21	-21	N/A
3/31/2018	2	-25	-21	-21	N/A
12/31/2017	6	-20	-13	-13	N/A
9/30/2017	22	-2	-12	-12	N/A
6/30/2017	23	3	3	3	N/A
3/31/2017	23	1	3	3	N/A
12/31/2016	18	-4	-3	-3	N/A
9/30/2016	1	-21	-3	-3	N/A
6/30/2016	N/A	-21	N/A	-18	N/A

Earnings vs Savings Rate: MEIP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MEIP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MEIP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MEIP's revenue (45.7% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: MEIP's revenue (45.7% per year) is forecast to grow faster than 20% per year.

Future ROE: Insufficient data to determine if MEIP's Return on Equity is forecast to be high in 3 years time